Jefferies Assumes Viridian Therapeutic (VRDN) at Buy

January 20, 2021 8:06 AM EST
Get Alerts VRDN Hot Sheet
Price: $14.00 +11.02%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 22
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Jefferies analyst Chris Howerton assumes coverage on Viridian Therapeutic (NASDAQ: VRDN) with a Buy rating and a price target of $28.00 (from $18.00).

The analyst commented, "Viridian (formerly miRagen) has a quick go-to-market strategy to be the 2nd IGF-1R (leadasset) approved in the $3B+ Thyroid Eye Disease market. The lead asset is clinically de-risked by the same validated MoA as TEPEZZA and could capture ~30% of the market.With solid execution and FDA cooperation, we think a 2025 launch is possible. We seefurther upside if VRDN can ‘rinse and repeat’ this strategy in more indications. Assumecoverage at Buy with a $28 PT."

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $ yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Jefferies & Co, FDA